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The organizational framework of community pharmacies in Europe 
Introduction 
According to the World Health Organization (WHO), people-centred and integrated health 
services are critical for reaching universal health coverage. A prerequisite for good health is 
access to preventive and curative health care.1   
This issue of access to care is still governed by many old lessons. It can be expressed in the 
five Á’s’: affordability (ability to pay for care), availability of care, ability to reach care 
(geographically), accommodation (adapted to the organizational needs of the client), and 
acceptability (from the clients perspective).2 Access to care implies enough health care 
professionals to cover the population served. Equity, another dimension of access to care, 
indicates that care must be available to all, regardless of their geographical location or social, 
economic and demographic situation.  
Recently, more emphasis has been put on primary care, as disease prevention is essential to 
ensure better health, and to a decreased use of more expensive secondary and tertiary care.3 
Community pharmacy is unquestionably an important part of primary care for various 
reasons. First, preventive and curative medicine often require the use of medicines, and these 
are in most countries typically (or exclusively) available from the pharmacy (traditional 
approach: product-based). Secondly, medicines may ideally (and increasingly) be delivered to 
the patient by employing clinical pharmacy principles for appropriate and rational use 
(intermediate approach: essential service).  In some European regions, forms of preventive 
care are practiced by community pharmacy, including screening activities, and health 
promotion campaigns (current approach: service development). Lastly, community 
pharmacies are easily accessibility, and often are the first point of contact between a care 
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provider and the patient. Because community pharmacy is part of primary care, the principles 
of access and equity are also valid for this sector of healthcare. Over the past decades, the 
pharmacy profession has developed, with pharmaceutical care putting an increasing focus on 
the patient certainly in Europe. 4 
Access to medicines especially by rural populations in some European countries has been a 
concern tackled in sparsely populated regions by the creation of legislation directed at the 
opening of new pharmacies ensuring equitable distribution.5 In some European countries such 
as Switzerland and the Netherlands, medical doctors may dispense medicines from their 
practice. 6,7 
It is interesting to note that community pharmacy practice is changing in the European Union 
and affiliated countries. These changes are facilitated (but also sometimes hindered) by 
national and European legislation, and active pharmacist or pharmacy organizations. Having a 
good overview of the health care systems in various European countries may help explaining 
and anticipating these changes.  
Between 2005 and 2007 a series of papers were published in the Annals of Pharmacotherapy, 
on the new pharmaceutical care related roles of pharmacy.8,9,10,11,12,13,14 In view of the rapid 
structural changes in Europe, a new overview seems necessary. 
The objectives are to list and compare health care and community pharmacy structure in 
Europe; and to discuss the facilitators and barriers that can be found in health care systems for 
the implementation of new community pharmacy services. Additionally, to better understand 
eventual differences arising, it was also intended to explore education and training of 
pharmacy staff. 
Method 
A cross-sectional observational study was conducted with a structured questionnaire. Data 
were collected using an online platform available between March and April 2013. A 
purposive sample of 31 representative individuals from 25 European countries was invited to 
participate. Respondents were selected based on their experience and visible contribution in 
pharmacy practice activities in their country and internationally, or by their engagement in 
political or scientific activities. To identify potential but less ‘visible’ respondents, a snowball 
sampling technique was used. 
Based on literature, a survey was specifically developed for this study. A series of articles 
entitled "Pharmacy around the world", published in the Annals of Pharmacotherapy from 
2005 to 2007, which characterized various aspects of the health systems, particularly the 
operating characteristics and regulation of community pharmacies in the country, and 
described care related services was central to the development of the survey tool.8   
The survey comprised five main sections: 
1. Description of the health care system (e.g. main provider, funding, etc.) 
2. Description of community pharmacies (e.g. regulation in place) 
3. Available products pharmacies and elsewhere 
4. Education and training of pharmacists and other auxiliary staff  
5. Services available through community pharmacies  
At the end, there was an open section where respondents were asked to mention relevant legal 
aspects that may have recently changed in their countries, conditioning accessibility to health 
care or to medicines. 
This survey was pre-tested by asking expert opinion on the content, format and wording used; 
three experts were involved practicing in different settings and representing a range of 
specialties. The final version can be found as electronic supplementary material to this paper. 
The information collected by the survey was then enriched and triangulated through an 
additional literature search, direct contact by email with pharmacists’ bodies, including the 
Pharmaceutical Group of the European Union in Brussels (PGEU), and clarification of some 
answers from respondents. The respondent from Iceland also referred to a report from the 
Boston Consulting Group (2011) where part of the data could be found.15 
Survey data were collected in the "Google docs" platform, which allows extraction by 
Microsoft Excel, version 2012. This database was then imported into the Statistical Package 
for Social Sciences (SPSS) version 19, for analysis. 
Results 
Data were collected between March and April 2013. Contact persons in 25 European 
countries were approached (Belgium, Bosnia, Croatia, Czech Republic, Denmark, England, 
Finland, Germany, Hungary, Iceland, Ireland, Italy, Malta, Northern Ireland, Norway, Poland, 
Portugal, Scotland, Serbia, Slovenia, Spain, Sweden, Switzerland, The Netherlands, and 
Wales). Of these, 17 contact persons responded to the survey and two additional countries 
were reached using a snowballing technique (Bulgaria and Macedonia). Responses obtained 
represent 19 countries and respondents worked either in professional associations representing 
community pharmacies or pharmacists or in the pharmacy practice department of universities 
(See table 1). The response rate in the study was 70.4%. However, if one considers that the 
snowball technique was expected to cover all European countries (n = 50, the United 
Nations), the response rate was only 38%.  
Health Care System 
Table 1 summarizes some features of the healthcare systems of European countries, including 
the predominance of the public or private sector, funding, coverage and accessibility for 
citizens. 
For the purpose of this paper, we have referred to “State organised”, which does not 
necessarily mean public. Public means organised so that the health care is accessible for 
everyone. State organised means that the state has organised the health care structure, but not 
necessarily the access. In the UK National Health Service’ (NHS) the healthcare organization, 
with different models of organisations across England, Scotland, Wales and Northern Ireland, 
funding is through direct taxation. 
  
Many professionals are state employees, and most health care institutions are state-owned, 
which may include hospitals, local health centers and tertiary care units. However, community 
pharmacy is often private, or corporately owned, with services being State remunerated or 
paid out of pocket by the patient. 
   
In the ‘Public System’, the state (or a state insurance) organizes and pays for healthcare 
services, but healthcare professionals are not necessarily state employed, and healthcare 
institutions are largely private. In the ‘Private System’, the state organizes and controls care, 
but citizens must be privately insured and the insurance companies pay for the care to the 
private institutions and care providers. There may be a state contribution directly to the 
insurance companies. 
 
In most respondent countries, there is a state regulated remuneration or insurance system, and 
co-payments may exist. Co-payments can be for non-remunerated or partially remunerated 
services and goods. In the Netherlands and Switzerland there is no state health insurance, but 
having a private health insurance is mandatory. In Ireland there is a mixed system, depending 
on the income of the citizen. 
  
Population coverage has been reported as ‘universal’, meaning for everyone in a country 
without limitations, as ‘all citizens’, meaning for every person living in a country and having 
the nationality of the country, and ‘all residents’, meaning all people who live officially in a 
country (but may have a different nationality). 
Please insert Table 1 here 
Community Pharmacy 
The regulation of community pharmacies ownership varies across Europe. In 3 of the 19 
countries in the sample, ownership is restricted to pharmacists (Denmark and Italy, multiple 
pharmacies; Spain, restricted to one). In most countries, ownership is open to any individual 
or entity, but there can be limitations. In, for instance, Portugal and Sweden, producers of 
medicinal products or Market Authorization Holders (MAH), and prescribers of medicinal 
products cannot own a pharmacy.  The most common situation is the possible ownership of 
multiple pharmacies by any individual/entity (n=16).  
In almost all the European countries surveyed, explicit criteria exist for the founding of new 
pharmacies. Ten countries (England, Portugal, Spain, Croatia, Malta, Italy, Belgium, 
Hungary, Denmark, Serbia) have criteria based on distance between pharmacies or number of 
people served. In Norway and Sweden a permit from the authorities is required before one can 
open a pharmacy, but the criteria for this permit focus more on solvency and the business 
model16. Macedonia, Iceland, and Ireland indicated that there are criteria, but which criteria 
were not clear. Only Switzerland and the Netherlands indicated to have no explicit criteria. In 
Belgium there currently is a moratorium on the opening of new pharmacies. No answer on 
this aspect was received from Bulgaria. 
The number of inhabitants per pharmacy was not reported by all. Therefore, data were 
supplemented with information from the PGEU from 2013. Denmark is the country with the 
greatest number of inhabitants per pharmacy (25.000) as opposed to Bulgaria (1750) (see 
figure 1). One should consider, however, that one pharmacy in Denmark may have several 
outlets. 
Please insert Figure 1 here 
Quality Management 
A quality management system (QMS) is a set of policies, processes and procedures required 
for planning, implementing and performing tasks in community pharmacies, which may lead, 
after an independent audit, to the accreditation of the pharmacy. Quality Management System 
for community pharmacies were reported to be available in 15 of the 19 responding countries.  
Countries reporting not to have a QMS for pharmacy were England, Macedonia, Ireland and 
Malta. 
Some countries indicated to have guidelines for the provision of pharmaceutical care in the 
pharmacy, such as the Netherlands, Hungary and Serbia. Examples in these countries include 
guidelines for diabetes, hypertension, dyslipidemia, obesity, asthma, chronic obstructive 
pulmonary disease (COPD), rhinitis, upper respiratory tract treatment (over-the counter, ahead 
referred to as OTC), dermatology (OTC and on prescription), gastro-intestinal tract disorders, 
benign prostate hyperplasia (BHP), pregnancy, back pain and geriatric medication 
management therapy. 
Products available at the pharmacy 
There are various categories of medicines available in pharmacies. The category of 
Prescription Only Medicines (POM), defined as a medicine which can only be sold through a 
pharmacy and for which a prescription is required, exists in all responding countries. 
Over-the-counter medicines, commonly known as OTC, are also available in all countries, but 
with some differences regarding the subcategories these include.  
Pharmacy Medicines (PM), defined as medicines only to be sold in pharmacies but without a 
prescription and under the (distant) supervision of a pharmacist, exist in all 19 responding 
European countries, except for Ireland and Portugal. In the latter country, however, a dispatch 
has been published that this category will be introduced soon, but the list is not ready yet. The 
non-prescription medicines may now be displayed and advertised, but cannot be purchased as 
a self-service good since they must  be placed behind the counter in a reserved area where 
only the pharmaceutical team can reach (this is true in pharmacies and in non-prescription 
medicines outlets, which may be in a specific area inside a supermarket or a petrol station. 
The category General Sales List (GSL) refers to medicines that are supposed to be relatively 
safe and can be sold in pharmacies, supermarkets and other places by non-pharmacist staff, 
and is available in 9 out of 19 countries (Table 2). In Macedonia, Spain, Bulgaria, Malta, 
Belgium and Serbia, medicines in general cannot be purchased outside of OTC points of sale, 
representing 31.6% of the participating countries.   
Other products that may be found in all European pharmacies are cosmetics, food 
supplements and medical devices. In most countries (17 out of 19), homeopathic products 
may also be available, reading glasses in 14 out of 19 countries and didactic toys in 7 out of 
the 19 responding countries (Table 2). 
Please insert table 2 here 
Education and training of pharmacists 
In Northern Ireland and Italy only pharmacists may practice in pharmacy.  However, in most 
countries the team is composed by pharmacists and pharmacy technicians. In Norway, it 
additionally includes assistants and nurses. In Sweden, there are also prescriptionists (Table 
3). The required qualifications for each team member are also described in Table 3. Please 
note that the requirements for technicians are usually expressed in years of education at a high 
school/college level, and often include practice work. Auxiliary staff preparation varies from 
short education to training on-the-job. 
Licenses 
The registration of pharmacists in most countries depends on Societies. In a few countries, the 
pharmacist societies are also the regulatory bodies, meaning that they control the licenses to 
practice and check the premises. However, this survey focused on their activity within a 
community pharmacy. These are generally subject to laws imposed by the national regulatory 
bodies (equivalent to EMA). Also, as small and medium sized companies that employ 
personnel, they may additionally be subject to the general work laws.  
Requirements for license renewal are requirements imposed by the competent bodies, which 
may include a minimum number of continuous professional development (CPD) credits (or 
hours), or an exam, to demonstrate competence in practice or others. The type of requirements 
varies widely and may include the simple registration with the Society, continuous 
professional development required by law and continuous professional development defined 
by the Pharmaceutical Society (or equivalent), where the latter may have various possible 
formats (Table 3). Additionally, there are several possible specializations in pharmacy, 
according to the sector of practice, and their recognition by the Pharmaceutical Societies (or 
equivalent) varies widely across Europe (Table 3). 
There are some exceptions where the boundaries between the Pharmaceutical Society and the 
Department of Health are different from most European countries. Since 2010, the registration 
of pharmacists in Great Britain is with the General Pharmaceutical Council (GPhC), the 
regulator for registered pharmacists, pharmacy technicians and pharmacy premises. In 
Northern Ireland, registration is with the Pharmaceutical Society of Northern Ireland, which 
also has a forum to support and develop professional activities: functions that are undertaken 
across Great Britain by the Royal Pharmaceutical Society (RPS). Pharmacy premises in 
hospital are regulated by the Care Quality Commission which regulates all hospital premises. 
  
Requirements for maintenance on the register in Great Britain include recording a minimum 
number of continuous professional development (CPD) entries. This is currently being 
reviewed by the GPhC as the revalidation of other health professionals is implemented, 
nominally called Continuing fitness to practice (CFtP). The support, development and 
recognition afforded by the RPS is widely regarded as a quality mechanism to demonstrate 
continuing fitness to practice, especially regarding the blend of self and peer assessment of 
advanced practice. Mechanisms to recognise specialisms and specialization and are also being 
developed in GB and across the UK.  
 
Please insert table 3 here 
 
Services available in community pharmacy 
Dispensing of medicines was universal across all the countries. Apart from this, the services 
more widely available in European pharmacies are smoking cessation programmes (93.8%, n 
= 15), followed by drug waste management programmes (81.3%, n = 13) and pharmaceutical 
care programmes (77.8%, n = 14). The least implemented services mentioned were drug 
administration (26.3%, n = 5) and prescription services (26.3%, n = 5) (Table 4). 
Please insert Table 4 here 
 
In 47% of the participating countries there is some sort of remuneration for pharmaceutical 
services, namely in Belgium, Denmark, England, Hungary, Ireland, Netherlands, Northern 
Ireland, Portugal, and Switzerland. 
 
Discussion 
The results of this study indicate that health care and pharmacy seem to be converging into 
one format, in which public funding is complemented by private funding (in the form of co-
payments of supplement insurances). Many new rules or laws are implemented by decisions 
made in the EU. Member countries must follow such directives, and thus the systems in EU 
countries converge. Privatization of healthcare only seems to be complete in the Netherlands 
and Switzerland, although some form of state-funding and control still exists.  
Community pharmacy ownership is no longer protected in most countries and currently there 
are only three countries where only pharmacists can own pharmacies, different to what was 
observed in Europe a decade ago. Interesting to note that in a few countries, physicians can 
own a pharmacy, although it seems to be discouraged if not absolutely necessary. Among 
countries where ownership is open to non-pharmacists, there are some where restrictions to 
ownership exist. In Portugal, for example, pharmacies may not be owned by pharmaceutical 
companies, wholesalers or medical doctors. In Sweden, medical doctors explicitly cannot own 
a pharmacy.  
The number of inhabitants served by pharmacies also seems to be converging, although it is 
still possible to observe a split between northern European countries and all others, with the 
first having larger pharmacies covering a larger number of inhabitants.  There were only two 
countries that reported to have no demographic criteria for the establishment of new 
pharmacies (Switzerland and the Netherlands), a finding consistent with PGEU data (PGEU, 
2010). 
The results about QMS for countries belonging to the United Kingdom should be carefully 
read as in these countries, pharmacists have had to be accredited. This accreditation enables 
the provision of specific services, which may be commissioned, i.e., requested by primary 
care doctors13. 
The technical staff of pharmacies comprises pharmacists in all countries and technicians in all 
except two countries (Italy and Northern Ireland). The inclusion of other categories is less 
clear, where in Sweden we may find prescriptionists, in Norway nurses, and in 6 countries 
(31.6%) auxiliary technicians. The prescriptionist is an individual with functions of 
medicines’ dispensing, with an equivalent role to the pharmacist, although with a lower 
qualification, as the course is 3-years.17 
As described in Directive 2005/36/EC of the European Parliament and of the Council of 7 
September 2005 on the recognition of professional qualifications, training the pharmacist is at 
least 5 years, with a minimum of 4 years of theoretical and 6 months of practical training in 
community pharmacy or hospital pharmacy, consistent with the information collected in the 
study18. 
The areas of specialization in England and Northern Ireland are hard to compare, as 
prescribing is an area of specialization but then the NHS also recognizes career paths, which 
may be seen as areas of specialization, such as the consultant pharmacists within hospital or 
pharmacists with special interests within community.   
Services implemented in community pharmacies across Europe are perhaps the domain of the 
survey where most variation was found. While some countries seem to be quite conservative 
and offer few services, others are even expanding to services traditionally embraced by other 
health care professions, such as immunization in Portugal or prescribing in England, Northern 
Ireland and Ireland. Indeed, this aspect is interesting and may possibly be related to various 
aspects, namely the accessibility of care in its traditional format, mostly in primary care19, 
which also includes the appropriate workforce to meet societal needs, but also eventually 
lobbying activities. However, the survey did not directly explore for the link between health 
care services available and arising community pharmacy services.  
The pharmaceutical services most widely disseminated in Europe, were dispensing (100.0%; 
n=19), smoking cessation (93.8%; n=15), and drug waste management programmes (81.3%; 
n=13), which is similar to the findings reported by Kanavos et al20. These authors also studied 
17 European countries and reported that these two services were available in all countries. 
The two services, however, clearly fall under the health promotion category. This indicates 
the relevance of the pharmacist’s role within the public health arena, but it also indicates that 
pharmacy (or pharmacist) specific services other than dispensing are more difficult to 
implement. 
Pharmaceutical care was the third more commonly reported service, indicated by 77.8% of the 
participating countries (n =14). However, one did not explore what components of 
pharmaceutical care were being delivered in each of the responding countries, perhaps an 
aspect worth further exploring in future work. Additionally, the level of implementation in the 
country was not assessed, neither was the understanding of the term pharmaceutical care 
assessed, a term that may encompass many clinical fields21, and these are two important 
limitations. It is important to reflect on the validity of the reported level of service provision, 
as it is much higher than what has been reported elsewhere15. In fact, the reported figure for 
this study is quite surprising given that pharmaceutical care services demand much more 
investment from the pharmacy human resources as it requires close patient monitoring, 
documentation, interaction with physicians and other members of the health care team.  
In only 47% of the responding countries there is remuneration (by the state or insurance) for 
pharmaceutical services. In other countries, the patient may be asked to pay (all or part of) the 
costs of the service. But this has not been explored in this study. Sometimes the 
implementation of some services on a larger scale becomes limited due to lack of 
remuneration, a barrier also to pharmaceutical care services previously identified.2223 
This study, like many studies in Europe, suffers from the fact that not all Europeans speak the 
same language. This means that questions are sometimes not understood correctly, or in the 
same manner, which may influence answers obtained. The research team have tried to deal 
with this by contacting respondents whenever such difficulties were obvious, and asking for 
additional explanations.  
This study also illustrates the difficulty to obtain information about community pharmacy in 
two big countries, France and Germany. In these two countries, the national bodies have 
limited information on the details of real practice and key data. Only the regional 
organisations detain this information. Hence, information about these countries is relatively 
hard to obtain, and validation of information is extra complicated. 
The quality of the information, which could not be triangulated, is a limitation. However, 
much of the information was checked and double-checked.  
Detailed information on remunerated services was lacking on this study, and this should be an 
interesting area to be further researched in the future, with particular interest in enhanced 
services, such as medication review and pharmaceutical care. 
Conclusion 
In general, all citizens have access to health care in European countries. The general features 
of community pharmacy across Europe are quite homogeneous, regarding products available 
and even regulations in place. The wider variability was found for services available in 
community pharmacies.  
 
Acknowledgements 
The authors would like to thank respondents to the survey by providing data on their country 
and by their availability to check data originating and constant availability to clarify authors. 
We specially thank Pharmaceutical Care Network Europe for providing the initial platform 
that resulted in this study. 
 
Declaration of Conflicting Interests 
The Authors declare that there is no conflict of interests. 
 
Funding Acknowledgement 
This research received no specific grant from any funding agency in the public, commercial, 
or not-for-profit sectors.  
 
 
 
 
References 
                                                     
1 World Health Organisation. Health Systems Service Delivery. In ‘Health Systems’. 
Available from: http://www.who.int/healthsystems/topics/delivery/en/ 
2 Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer 
satisfaction. Med Care 1981;19:127-40. 
3 Goodman RA, Bunnell R, Posner SF. What is "Community Health"? Examining the 
Meaning of an Evolving Field in Public Health. Prev Med 2014; 67:28-61. 
4 van Mil JWF, Schulz M. A review of Pharmaceutical Care in Community Pharmacy in 
Europe. Harvard Health Policy Review 2006; 7(1):155-68. 
5 Vogler S, Arts D, Sandberger K. Impact of pharmacy deregulation and regulation in 
European countries. Summary Report. Vienna, 2012. Gesundheit Österreich, Vienna. 
6 Guignard E, Bugnon O. Pharmaceutical Care in Community Pharmacies: Practice and 
Research in Switzerland. Ann Pharmacother 2006; 40:512-7. 
7 Deuning CM. Number of GPs with a pharmacy per municipality (Aantal apotheekhoudende 
huisartsen per gemeente 2014). In: Volksgezondheid Toekomst Verkenning, Nationale Atlas 
Volksgezondheid. Bilthoven: RIVM, 
http://www.zorgatlas.nl/zorg/eerstelijnszorg/farmaceutische-zorg/aantal-apotheekhoudende-
huisartsen-per-gemeente-2009/ 
8 Farris KB, Fernandez-Llimos F, Benrimoj SI. Pharmaceutical Care in Community 
Pharmacies: Practice and Research from Around the World. Ann Pharmacother. 2005; 
39:1539-41. 
9 Gastelurrutia MA, Faus MJ, and Fernández-Llimós F. Providing Patient Care in Community 
Pharmacies in Spain. Ann Pharmacother 2005;39:2105-10. 
10 Costa S, Santos C, and Silveira J. Community Pharmacy Services in Portugal. Ann 
Pharmacother 2006;40:2228-34. 
                                                                                                                                                                      
11 Westerlund LOT, Björk T. Pharmaceutical Care in Community Pharmacies: Practice and 
Research in Sweden. Ann Pharmacother 2006; 40:1162-9. 
12 Van Mil JWF. Pharmaceutical Care in Community Pharmacy: Practice and Research in the 
Netherlands. Ann Pharmacother 2005;39:1720-5. 
13 Noyce PR. Providing Patient Care through Community Pharmacies in the UK: Policy, 
Practice, and Research. Ann Pharmacother 2007;41:861-8. 
14 Herborg H, Sorensen E.W, and Frokjaer B. Pharmaceutical care in community pharmacies: 
practice and research in Denmark. Ann Pharmacother 2007; 41 (4):681-689. 
15 The Boston Consulting Group. Health Care System reform and short term savings 
opportunities, Iceland Health Care System project. Available from: 
http://www.velferdarraduneyti.is/media/ritogskyrslur2011/IIceland_HCS-Final_report-
_Long_version.pdf 
16 Swedish Law on sales of medicinal products (SFS 2009:366) 
17 Westerlund L.O.T. and Björk H.T. Pharmaceutical Care in Community Pharmacies: 
Practice and Research in Sweden. Ann Pharmacother 2006;40:1162-9. 
18 Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 
on the recognition of professional qualifications. Official Journal of the European Union. 
2005. 
19 Augusto GF. Cuts in Portugal’s NHS could compromise care. Lancet. 2012; 379:400. 
 
20 Kanavos P, Schurer W, Vogler S. atahe Pharmaceutical distribution chain in the European 
Union: Structure and impact on pharmaceutical prices. London/Vienna. 2011. 
21 Allemann SS, van Mil JW, Botermann L, Berger K, Griese N, Hersberger KE. 
Pharmaceutical care: the PCNE definition 2013. Int J Clin Pharm 2014;36 (3):544-55. 
                                                                                                                                                                      
22Hughes, CM, Hawwa, AF, Scullin, C, Anderson, C, Bernsten; CB, Bjornsdottir, I, Cordina, 
MA, Costa, FA, et al.  Provision of pharmaceutical care by community pharmacists: a 
comparison across Europe. Pharm World Sci. 2010; 32(4):472-87. 
23Chan P, Grindrod K, Bougher D, et al. A systematic review of remuneration systems for 
clinical pharmacy care services - Clinical Review. Canadian Pharmacists Journal. 
2008;141(2):102-110.  
 
 
  
 
Fig. 1 Average number of people served per pharmacy (* = numbers according to 
PGEU)1 
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Table 1 Basic financial characteristic of health care systems in a number of European 
countries 
 Nature of 
health service 
Financing of Health service Population coverage Private health 
insurance 
Belgium State 
organized 
Taxes plus personal 
premiums based on income 
and employment 
All citizens Optional 
Bulgaria State 
organized 
Taxes and premiums Universal Optional 
Croatia State 
organized 
Taxes and premiums, co-
payments 
All citizens Optional 
Denmark State 
organized 
Taxes All citizens Optional 
England State 
organized 
Taxes and co-payments All citizens Optional 
Hungary State 
organized 
Taxes and co-payments Universal Optional 
Ireland State 
organized and 
private 
Co-payments depend upon 
income 
All citizens Optional  
Iceland State 
organized 
Taxes All citizens Optional but 
rare 
Italy State 
organized 
Taxes and co-payments All residents Optional 
Macedonia State 
organized 
Taxes Free for employed or 
officially unemployed. 
Optional 
Malta Public and 
private 
Taxes and private All citizens Optional 
Netherlands Private Partially private, partially 
taxes with co-payments 
All citizens Compulsory 
N. Ireland State 
organized 
Taxes All citizens Optional 
Norway State 
organized 
Taxes All citizens Optional, but 
rare 
Portugal State 
organized 
Taxes and co-payments Universal Optional 
Serbia State 
organized 
Taxes All citizens Optional 
Spain State 
organized 
Taxes Universal Optional 
Sweden State 
organized 
Taxes All residents Optional 
Switzerland Public and 
private 
Partially private, partially 
taxes with co-payments 
All citizens Compulsory 
 
table 1
Click here to download table: Table 1 Characteristic of health care systems 97-2003.doc 
Table 2   Products sold in pharmacies 
 
O 
T 
C 
P 
M 
P 
O 
M 
G 
S 
L 
Other products sold in pharmacies Sale of 
medicines 
outside 
pharmacie
s 
Cosme
-tics 
Food 
Supple
-ments 
Medica
l 
devices 
Homeo-
pathic 
product
s 
Readin
g 
Glasses 
Didacti
c Toys 
Belgium Y Y Y N Yes Yes Yes Yes Yes No No 
Bulgaria Y Y Y N Yes No Yes Yes No No No 
Croatia Y Y Y N Yes Yes Yes Yes Yes No Yes 
Denmark Y Y Y Y Yes Yes Yes Yes Yes No Yes 
England Y Y Y Y Yes Yes Yes Yes Yes Yes Yes 
Hungary Y Y Y N Yes Yes Yes Yes No No Yes 
Ireland Y N Y Y Yes Yes Yes Yes Yes No Yes 
Iceland Y Y Y Y Yes Yes Yes Yes Yes Yes Yes 
Italy Y Y Y Y Yes Yes Yes Yes Yes Yes Yes 
Macedonia Y Y Y N Yes No Yes Yes No No No 
Malta Y Y Y N Yes No Yes No Yes Yes No 
Netherland
s 
Y Y Y N Yes Yes Yes Yes No No Yes 
N. Ireland Y Y Y Y Yes Yes Yes Yes Yes Yes Yes 
Norway Y Y Y Y Yes Yes Yes Yes Yes No Yes 
Portugal Y N Y N Yes Yes Yes Yes Yes Yes Yes 
Serbia Y Y Y N Yes Yes Yes Yes Yes Yes No 
Spain Y Y Y N Yes Yes Yes Yes Yes Yes No 
Sweden Y Y Y Y Yes Yes Yes No Yes No Yes 
Switzerlan
d 
Y Y Y Y Yes Yes Yes Yes Yes Yes Yes 
 
Y = Yes N=No 
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Table 3: Staff working in a pharmacy, with required qualifications and Type of Licenses and licensing for pharmacists 
a) 
5 years university education including 6 months practice;
*
  
e) 
2-3 year course, partially in practice UD =   Undefined           SC= Special Case, see discussion 
b)
 5 years university education including 1 year practice;  
f)
 3 year course    
* The Bologna Declaration of 19 June 1999 
c)
 6 years education including 1 year practice   
g)
 4 years course 
d)
 2 years course       
h) 
other 
                                                     
 
 Technical team of pharmacy Requirements to keep the license to practice Recognized Areas of Specialization  
 
P
h
ar
m
ac
is
ts
 
P
h
ar
m
ac
y 
Te
ch
n
ic
ia
n
s 
P
h
ar
m
ac
y 
au
xi
lia
ry
 s
ta
ff
 
N
u
rs
e
s 
P
re
sc
ri
p
ti
o
n
is
ts
 
R
e
gi
st
ra
ti
o
n
 
w
it
h
 t
h
e
 
So
ci
e
ty
 
C
o
n
ti
n
u
o
u
s 
p
ro
fe
ss
io
n
al
 
d
e
ve
lo
p
m
e
n
t 
re
q
u
ir
e
d
 b
y 
la
w
 
C
o
n
ti
n
u
o
u
s 
p
ro
fe
ss
io
n
al
 
d
e
ve
lo
p
m
e
n
t 
d
e
fi
n
e
d
 b
y 
th
e
 
re
gu
la
to
ry
 
b
o
d
y 
H
o
sp
it
al
 
P
h
ar
m
ac
y 
C
lin
ic
a
l 
A
n
al
ys
is
 
P
h
ar
m
a-
ce
u
ti
ca
l 
In
d
u
st
ry
 
C
o
m
m
u
n
it
y 
P
h
ar
m
ac
y 
R
e
gu
la
to
ry
 
A
ff
a
ir
s 
P
re
sc
ri
b
in
g 
Belgium Yes
 a)
 Yes No No No Yes No No Yes No Yes No No No 
Bulgaria Yes
 a)
 Yes
f)
 No No No Yes No Yes No Yes Yes No No No 
Croatia Yes
 a)
 Yes No No No No Yes Yes No No No Yes No No 
Denmark Yes
 a)
 Yes
f)
 No No No - - - - - - - - No 
England Yes
 b)
 Yes
h)
 Yes No No No No Yes SC No No SC No Yes 
Hungary Yes
 a)
 Yes
d)
 No No No Yes Yes Yes Yes Yes Yes Yes Yes No 
Ireland Yes
 b)
 Yes
d)
 Yes No No Yes Yes Yes No No No No No No 
Iceland Yes
 a)
 Yes Yes No No UD UD UD UD UD UD UD UD No 
Italy Yes
 a)
 No No No No Yes No Yes Yes No No No No No 
Macedonia Yes
 a)
 Yes
g)
 No No No No Yes No Yes No No No Yes No 
Malta Yes
 a)
 Yes Yes No No No No Yes No No No No No No 
The Netherlands Yes
 a) 
Yes
e)
 Yes No No No Yes No Yes No No Yes No No 
Northern Ireland Yes
 b)
 No No No No Yes No Yes No No No No No Yes 
Norway Yes
 a)
 Yes Yes Yes Yes No No No Yes No No Yes No No 
Portugal Yes
 a)
 Yes
g)
 Yes
h)
 Yes No Yes Yes Yes Yes Yes Yes No Yes No 
Serbia Yes 
c) 
Yes
h)
 No No No Yes Yes Yes Yes Yes Yes Yes Yes No 
Spain Yes
 a)
 Yes
d)
 Yes No No Yes No No Yes Yes Yes No No No 
Sweden Yes
 a)
 Yes
h)
 Yes Yes Yes No Yes Yes No No No No No No 
Switzerland Yes
 a)
 Yes Yes No No Yes Yes Yes Yes Yes No Yes No No 
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Table 4 Services available in community pharmacies in Europe 
 
 
 
Country 
H
o
m
e 
ca
re
 s
u
p
p
o
rt
 
A
d
m
in
is
tr
at
io
n
 o
f 
m
ed
ic
in
es
 
e.
g.
 in
je
ct
ab
le
 d
ru
gs
) 
A
d
m
in
is
tr
at
io
n
 o
f 
va
cc
in
es
 
M
ed
ic
al
 a
p
p
o
in
tm
en
ts
 
(e
.g
.N
u
tr
it
io
n
) 
co
n
su
lt
at
io
n
s 
M
ea
su
re
m
en
t 
o
f 
b
io
lo
gi
ca
l 
an
d
 b
io
ch
em
ic
al
 p
ar
am
et
er
s 
P
h
ar
m
ac
eu
ti
ca
l c
ar
e 
p
ro
gr
am
m
es
 
Sm
o
ki
n
g 
ce
ss
at
io
n
 p
ro
gr
am
m
e
 
N
ee
d
le
 E
xc
h
an
ge
 p
ro
gr
am
m
e
 
M
ed
ic
at
io
n
 R
ev
ie
w
 
D
ru
g 
w
as
te
 m
an
ag
e
m
en
t 
p
ro
gr
am
m
e
 
P
re
sc
ri
b
in
g 
P
ro
vi
si
o
n
 o
f 
W
ri
tt
en
 
St
an
d
ar
d
iz
e
d
 In
fo
rm
at
io
n
 
Belgium Yes
a)
 No No No No Yes
 
a)
 
Yes
 
a)
 
Yes
 
a),c)
 
No Yes
 
a),c)
 
No Yes
 
a),c)
 
Bulgaria No No No Yes
 
a)
 
Yes
 
a)
 
Yes
 
a)
 
Yes
 
a)
 
- Yes
 a)
 - No Yes
 
a),f) 
Croatia No No No Yes
 
a)
 
- No Yes
 
a)
 
- No Yes
 a)
 No No 
Denmark Yes
 a)
 No No No Yes
 
c)
 
Yes
 
a),c)
 
Yes
 
a),c)
 
No Yes
 a)
 Yes
 
a),c)
 
No No 
Spain No No No Yes
 
e) 
Yes Yes
  
a)
 
Yes
 
a)
 
Yes
 a)
 Yes
 a)
 Yes
 a)
 No Yes
 a)
 
Netherlands Yes
 a)
 No No Yes
 
a)
 
Yes Yes
 
a)
 
Yes
 
a)
 
Yes Yes
 a)
 Yes No Yes 
Hungary No No No Yes
 
a)
 
Yes Yes
 
a)
 
Yes
  
a)
 
No Yes
 a)
 Yes
 
a),c)
 
No No 
England Yes
 a)
 Yes
 a)
 Yes
 
a)
 
Yes
 
a)
 
Yes Yes
 
a)
 
Yes
 
a)
 
Yes - Yes Yes Yes 
Ireland No - Yes
 
a)
 
- Yes
 
a),c)
 
No - Yes
 a)
 No Yes Yes No 
N. Ireland No No Yes
 
a)
 
No No Yes
 
a)
 
Yes
 
a)
 
Yes
 a)
 Yes
 a)
 Yes
 a)
 Yes
 
a) 
No 
Iceland 
 
No No Yes 
d)
 
Yes Yes No Yes No No Yes No No 
Italy Yes
 a)
 No Yes
 
a)
 
Yes
 
a)
 
Yes Yes
 
a)
 
Yes
 
a)
 
Yes
a)
 Yes
 a)
 Yes
 a)
 No Yes
 a)
 
Macedonia 
 
No Yes
 a),c)
 No No Yes
 
c)
 
No No No No No No No 
Malta 
 
No No No Yes Yes
 
a)
 
No No Yes
 a)
 No No No No 
Norway No No No Yes
 
a)
 
No Yes
  
a)
 
Yes
 
a)
 
Yes Yes
a)
 Yes No Yes 
Portugal Yes
 a)
 Yes
 a)
 Yes
 
a)d)
 
Yes
 
e)
 
Yes
  
a)
 
Yes
 
a)
 
Yes
 
a)
 
No* Yes
a)
 Yes
 
a),c)
 
No Yes
 
a),c)
 
Serbia No No No No No Yes
 
a)
 
No No Yes
a)
 No No Yes 
Sweden Yes
 
a),b)
 
No No No No Yes
 
a),b)
 
Yes
 
a),b)
 
No Yes
a),b)
 Yes
 
a),b)
 
No Yes
 
a),c)
 
Switzerland 
 
Yes
d)
 Yes
 a)
 No Yes
d)
 Yes
 
a)
 
Yes
 
a)
 
Yes Yes No Yes
d)
 No  Yes
d)
 
a)
 Service provided by pharmacists;  
b)
 Service provided by prescriptionists;  
c)
 Service provided by pharmacy technicians 
d)
 Service provided by nurses 
e)
 Service provided by nutritionists as part of the service ;   
f)
 Service provided by 
other professional; 
*) yes, since 1993; suspended during 2014, expected to restart in 2015 
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